Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

Growth Hormone Treatment in Short Children Born Small for Date (Genotonorm)

NCT00174408•Pfizer

Summary

The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)

Eligibility

Age

3 - 7 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Birth length below -2 SD
•Height at start below - 2 Sd

Exclusion Criteria

•Any endocrine or chronic disease
•Any known syndrome with short stature

Key Dates

Start Date

March 1, 1990

Completion Date

February 1, 2005

Last Updated

May 3, 2007

Enrollment

110

Estimated participants

Conditions

Growth Disorders

Interventions

Genotropin

DRUG

Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months

NCT06662045

Iron-Deficiency AnemiaNeurobehavioral Manifestations+2 more

View study

ACTIVE_NOT_RECRUITINGPHASE2

Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

NCT05382637

Growth Disorders

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 3, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

Inclusion Criteria

Exclusion Criteria

Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months

Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)

Bone Age Assessment in Children Using Ultrasound Compared to Wrist X-ray

Observational Study of Somatropin Treatment in Children